Compare NBTX & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | OMCL |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2018 | 2000 |
| Metric | NBTX | OMCL |
|---|---|---|
| Price | $37.81 | $42.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $36.00 | ★ $55.83 |
| AVG Volume (30 Days) | 67.4K | ★ 733.1K |
| Earning Date | 03-31-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $787,309,000.00 |
| Revenue This Year | $58.17 | $6.77 |
| Revenue Next Year | N/A | $5.22 |
| P/E Ratio | ★ N/A | $167.72 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $4.79 | $26.85 |
| 52 Week High | $57.14 | $51.84 |
| Indicator | NBTX | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 59.78 |
| Support Level | $30.15 | $35.81 |
| Resistance Level | $38.29 | $45.06 |
| Average True Range (ATR) | 2.46 | 1.72 |
| MACD | 0.45 | 0.41 |
| Stochastic Oscillator | 67.69 | 90.03 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.